Veterinary mRNA and biologics

An mRNA vaccine delivers instructions rather than an antigen. A synthetic messenger RNA encoding a pathogen protein is packaged in a lipid nanoparticle, taken up by host cells, and translated on the cell’s own ribosomes; the resulting protein is processed and presented, generating antibody and cellular responses to a protein the animal made itself. Modified nucleosides — pseudouridine in particular — reduce recognition of the synthetic RNA by innate sensors, which raises translation and lowers unwanted inflammation. None of this differs between species.

What the platform actually buys

The relevant property for animal health is not that mRNA generates a better response than a well-made inactivated or subunit vaccine. Often it does not. The property is that the manufacturing process is sequence-agnostic: the enzymatic transcription reaction, the purification and the encapsulation are the same regardless of what the RNA encodes, so changing the target strain is a change of template rather than a change of process. Conventional veterinary vaccine manufacture usually requires growing the pathogen — in eggs, in cell culture — which means new isolates take time to adapt and yields vary by strain.

That difference matters most where a pathogen changes fast and a decision must be made inside a season: influenza in poultry and swine, foot-and-mouth serotypes, and outbreak response generally. It also matters where the pathogen is dangerous or difficult to culture, since mRNA manufacture never requires handling live agent. A further practical advantage is that a vaccine encoding a single protein is inherently compatible with distinguishing infected from vaccinated animals, which is central to trade status for several notifiable diseases.

Why the calculus differs from human medicine

Two constraints dominate and both are economic rather than biological. The first is cost per dose against the value of the animal. A vaccine priced acceptably for a person is unusable in a broiler flock where the entire margin per bird is small, and a lipid nanoparticle formulation is not cheap: the ionisable lipid, the encapsulation step and the RNA all cost. This is why the earliest veterinary applications cluster at the high-value end — horses, companion animals, individually valuable breeding stock — and at outbreak use, where the alternative is culling.

The second is the cold chain. Human mRNA products were initially distributed frozen, and stability at refrigerator temperature has improved but remains formulation-specific. Veterinary distribution frequently ends at a farm, a remote holding or a field vaccination team, and the further from a laboratory the last mile is, the more a frozen product is unusable. Thermostability is therefore not a convenience feature in this sector; it is the gating requirement, and it is a formulation problem — lipid composition, lyophilisation, excipients — rather than a question about the RNA.

Where it is being used in practice is narrower than the platform’s coverage suggests: authorised veterinary products remain few, and mRNA sits alongside recombinant subunit and viral-vector approaches rather than replacing them. The honest current claim is about response time and manufacturing flexibility, not superiority of immune response.